RT Journal Article
SR Electronic
T1 Ultra-Sensitive High-Resolution Profiling of Anti-SARS-CoV-2 Antibodies for Detecting Early Seroconversion in COVID-19 Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.28.20083691
DO 10.1101/2020.04.28.20083691
A1 Maia Norman
A1 Tal Gilboa
A1 Alana F. Ogata
A1 Adam M. Maley
A1 Limor Cohen
A1 Yongfei Cai
A1 Jun Zhang
A1 Jared E. Feldman
A1 Blake M. Hauser
A1 Timothy M. Caradonna
A1 Bing Chen
A1 Aaron G. Schmidt
A1 Galit Alter
A1 Richelle C. Charles
A1 Edward T. Ryan
A1 David R. Walt
YR 2020
UL http://medrxiv.org/content/early/2020/05/02/2020.04.28.20083691.abstract
AB The COVID-19 pandemic continues to infect millions of people worldwide. In order to curb its spread and reduce morbidity and mortality, it is essential to develop sensitive and quantitative methods that identify infected individuals and enable accurate population-wide screening of both past and present infection. Here we show that Single Molecule Array assays detect seroconversion in COVID-19 patients as soon as one day after symptom onset using less than a microliter of blood. This multiplexed assay format allows us to quantitate IgG, IgM and IgA immunoglobulins against four SARS-CoV-2 targets, thereby interrogating 12 antibody isotype-viral protein interactions to give a high resolution profile of the immune response. Using a cohort of samples collected prior to the outbreak as well as samples collected during the pandemic, we demonstrate a sensitivity of 86% and a specificity of 100% during the first week of infection, and 100% sensitivity and specificity thereafter. This assay should become the gold standard for COVID19 serological profiling and will be a valuable tool for answering important questions about the heterogeneity of clinical presentation seen in the ongoing pandemic.Competing Interest StatementDavid Walt has a financial interest in Quanterix Corporation, a company that develops an ultra-sensitive digital immunoassay platform. He is an inventor of the Simoa technology, a founder of the company and also serves on its Board of Directors. Dr. Walt’s interests were reviewed and are managed by BWH and Partners HealthCare in accordance with their conflict of interest policies. The assays in this publication have been licensed by Brigham and Women’s Hospital to Quanterix Corporation.Funding StatementThis work was largely funded through a grant from the Massachusetts Consortium for Pathogen Resilience. In addition, support came from the Global TravEpiNet (GTEN) system sponsored by the US Centers for Disease Control and Prevention (Grant No. U01CK000490: ETR, RCC) as well as a T32GM007753 grant from NIGMS, a T32 AI007245 from NIAID, and an R01AI146779 from NIAID.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors declare that the data supporting the findings of this study are available within the paper and its Supplementary information files.